Clinical Trials

Thoracical Tumors

Recruitment stopped
Ongoing Recruitment

CINC wt-Studie (Novartis CINC280A2201)

(second-line)
Title:A Phase II, Multicenter, Three-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02414139
EudraCT: 2014-003850-15 (siehe EU klinisches Studienregister)

BioNTech –Forschungsstudie (RB_T002)

(diagnostisch, Früherkennung, Screening)
Title:Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität
Indication:-
Type of study:Phase N/A
Contact: Sebastian Schülke (Study Nurse)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Dirk Jäger (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PET-CT__PET-MRT bei BC

(diagnostisch, Screening)
Title:Vergleich der diagnostischen Genauigkeit von FDG-PET/CT und FDG-PET/MRT einschließlich Diffusionsgewichteter MRT beim präoperativen Staging von Patienten mit Nicht-kleinzelligem Bronchialkarzinom.
Indication:n.a.
Type of study:Phase N/A
Contact: Radiologie DKFZ (Kontaktperson)
[-]
Investigator: Prof. Dr. Heinz-Peter Schlemmer (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

INKA-Studie

(radiologisch)
Title:Ionentherapie bei nicht-kleinzelligen Pancoast-Tumoren im trimodalen Behandlungskonzept: Die INKA-Studie
Indication:Lunge
Type of study:Phase N/A
Contact: Prof. Dr. med. Klaus Herfarth (Kontaktperson)
[Klaus.Herfarth@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Klaus Herfarth (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Blueprint / BLU-667-1101

Title:A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:Carcinoma, Non-Small-Cell LungLung Neoplasms
Type of study:Phase I
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03037385
EudraCT: 2016-004390-41 (siehe EU klinisches Studienregister)

CRISP / AIO-TRK-0315

Title:Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients
Indication:Carcinoma, Non-Small-Cell LungLung Neoplasms
Type of study:Phase
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02622581
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Canakinumab

Title:A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03447769
EudraCT: 2017-004011-39 (siehe EU klinisches Studienregister)

DURATION / AIO-YMO/TRK-0416

Title:Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Indication:CarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinoma
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03345810
EudraCT: 2016-003963-20 (siehe EU klinisches Studienregister)

FORCE

Title:Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
Indication:CarcinomaLung NeoplasmsAdenocarcinomaCarcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr.med. Farastuk Bozorgmehr (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03044626
EudraCT: 2015-005741-31 (siehe EU klinisches Studienregister)

HeiMeKom

Title:Heidelberger Meilenstein-Kommunikationskonzept (HeiMeKOM) - Eine Mixed-Method Studie
Indication:Metastasiertes Lungenkarzinom
Type of study:Phase N/A
Contact: Anja Siegle (Kontaktperson)
[Anja.Siegle@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Leiter klinische Prüfung)
Trial Register: Die Studie ist beim "DRKS - Deutsches Register Klinischer Studien" registriert. Siehe DRKS00013469
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

MERU / M16-298

Title:A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Indication:Lung Neoplasms Small Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03033511
EudraCT: 2016-003503-64 (siehe EU klinisches Studienregister)

NEOMUN

Title:Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN]
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03197467
EudraCT: 2017-000105-20 (siehe EU klinisches Studienregister)

PROMISE

Title:Prädiktive immunologische Signaturen bei Lungenkrebs
Indication:Nicht-kleinzelliges Lungenkarzinom = non small cell lung cancer (NSCLC)
Type of study:Phase N/A
Contact: Jennifer Rehberger (Study Nurse)
[Jennifer.Rehberger@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Dirk Jäger (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Pembro Ipi Firstline / MK-3475-598

Title:A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03302234
EudraCT: 2016-004364-20 (siehe EU klinisches Studienregister)

Pfizer Lorlatinib / B7461006

Title:A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03052608
EudraCT: 2016-003315-35 (siehe EU klinisches Studienregister)

Roche B-FAST / BO29554

Title:A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase II/III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03178552
EudraCT: 2017-000076-28 (siehe EU klinisches Studienregister)

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)

TAHOE / M16-289

Title:A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03061812
EudraCT: 2016-003726-17 (siehe EU klinisches Studienregister)

VISION / MS200095-0022

Title:A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02864992
EudraCT: 2015-005696-24 (siehe EU klinisches Studienregister)

Vaccibody (VBN-01)

Title:An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
Indication:Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN
Type of study:Phase I
Contact: Sebastian Schülke (Kontaktperson)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: PD Dr. med. Jürgen Krauss (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2017-002474-39 (siehe EU klinisches Studienregister)